Shinshin Pharmaceutical Establishes In-House Research Facility for World's First Developed Microneedle Drug... "Shortening Development Time"

Transdermal drug delivery platform company Shinshin Pharmaceutical announced on the 11th that it has completed the establishment of its own research facilities for the development of next-generation microneedle pharmaceuticals. Shinshin Pharmaceutical plans to accelerate the development of the world's first microneedle pharmaceuticals through its proprietary microneedle-related technology and facilities.

Shinshin Pharmaceutical introduced coating equipment to load drugs applied with microsphere technology onto microneedles and has completed internal verification and trial operation. With the establishment of these facilities as a milestone, research on additional microneedle formulations will be possible, and the development period for therapeutics is also expected to be shortened. Previously, research microneedles were produced using external equipment, which incurred additional time and costs.

Shinshin Pharmaceutical is developing coated microneedle pharmaceuticals using its own facilities. Unlike dissolving microneedles where the needle itself is the drug, coated microneedles load the drug by coating it on the needle surface, minimizing the possibility of side effects caused by overdose. It is also applicable to heat-sensitive drugs, broadening the range of drugs that can be loaded. The drying time is short, and only an appropriate amount of drug is used, maximizing production efficiency.

A Shinshin Pharmaceutical official said, “We have succeeded in establishing research facilities optimized for Shinshin Pharmaceutical’s microsphere technology,” adding, “We will develop microneedle pharmaceuticals applied with next-generation drug delivery technology microspheres to diversify our drug portfolio and lay the foundation for overseas expansion.”

He continued, “The first microneedle pharmaceutical, a topical arthritis treatment, is currently undergoing preclinical research, and after confirming efficacy, we will promptly proceed with related procedures such as applying for IND (Investigational New Drug) for Phase 1 clinical trials.”

Shinshin Pharmaceutical has secured microsphere technology that maximizes drug delivery effects when loading drugs onto microneedles by utilizing TDDS (Transdermal Drug Delivery System) technology. After filing two patents, additional patents are also being prepared. Since 2021, the company has continued industry-academic-research cooperation, including signing a business agreement with Gachon University for joint development of microneedle pharmaceuticals.

Microsphere is a next-generation drug delivery technology independently developed by Shinshin Pharmaceutical. Microspheres are characterized by maximizing solubility and bioavailability through molecular size reduction and amorphization processes for drug loading within microneedles.

This content was produced with the assistance of AI translation services.